Evaluation of the Practice of Three Morning Sputa on NCT00212550

Updated 05/17/2024

Clinical Trial Details — Status: Completed

Administrative data
NCT number	NCT00212550
Other study ID #	9250-04B
Secondary ID
Status	Completed
Phase	N/A
First received	September 13, 2005
Last updated	June 20, 2012
Start date	November 2006

Study information
Verified date	June 2012
Source	New York University School of Medicine
Contact	n/a
Is FDA regulated	No
Health authority	United States: Institutional Review Board
Study type	Observational

Clinical Trial Summary

Obtain sputum smears within one day to rule out TB

Recruitment information / eligibility
Status	Completed
Enrollment	10
Est. completion date
Est. primary completion date
Accepts healthy volunteers	Accepts Healthy Volunteers
Gender	Both
Age group	N/A and older
Eligibility	Inclusion Criteria: - All subjects admitted to Bellevue Hospital for evaluation of possible TB Exclusion Criteria: - Unable to produce spontaneous or induced sputum

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

Pulmonary TB

Intervention

Procedure:
• Obtain standard three daily sputum samples vs. three samples on the first day for the diagnosis of pulmonary TB.
Sputum induction

Locations
Country	Name	City	State
United States	NYU School of Medicine Division of Pulmonary and Critical Care	New York	New York

Sponsors *(1)*
Lead Sponsor	Collaborator
New York University School of Medicine

Country where clinical trial is conducted

United States,

See also
	Status	Clinical Trial	Phase
	Completed	`NCT00933790` - Comparing Daily vs Intermittent Regimen of ATT in HIV With Pulmonary Tuberculosis	Phase 3
	Completed	`NCT04645836` - Impact of a Pharmacist-led Patient-centred Care Intervention Along With Text-Message Reminders, on the Management of Newly Diagnosed Tubercular Patients: a Protocol for a Randomized Controlled Trial'.	N/A
	Recruiting	`NCT06058299` - Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary Tuberculosis	Phase 2
	Completed	`NCT03722472` - Phase 1 Clinical Trial of Single-Vial ID93 + GLA-SE in Healthy Adults	Phase 1
	Completed	`NCT03678688` - A Phase 1/2 Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis	Phase 1/Phase 2
	Recruiting	`NCT03025516` - Performance Evaluation of TB Breath- and Cough-testing Platforms	N/A
	Completed	`NCT02961569` - Comparison Between Two Strategies for the Diagnosis of TB	N/A
	Recruiting	`NCT05426720` - Risk Factors and Biomarkers for Post-tuberculosis Lung Damage
	Recruiting	`NCT04264221` - Promoting Overall Care and Management Related to Tuberculosis Infection Through Pharmaceutical Care and Text Messaging	N/A
	Active, not recruiting	`NCT05221502` - Safety and Efficacy Evaluation of 4-month Regimen of OPC-167832, Delamanid and Bedaquiline in Participants With Drug-Susceptible Pulmonary TB	Phase 2